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Abstract 
A comparison of the current structures and dynamics of UK and German biotech-
nology-based industries reveals a striking convergence of industrial organisations 
and innovation directions in both countries. This counteracts propositions from 
theoretical frameworks such as the varieties-of-capitalism hypothesis and the na-
tional innovation systems approach which suggest substantial differences between 
the industrial structures of the countries due to differing institutional frameworks. 
In this paper, we question these approaches and show that the observed structural 
alignment can be explained by the network organisation of research and produc-
tion in knowledge-based industries. 
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1 Introduction 
In knowledge-based economies the 
mechanisms of knowledge creation 
and utilisation are changing. Industrial 
economics and new innovation theory 
consider the increasing complexity of 
knowledge, the accelerating pace of 
the creation of knowledge, and the 
shortening of industry life cycles to be 
responsible for the rising importance 
of innovation networks. Knowledge-
intensive industries such as IT and 
biotechnology have already undergone 
structural changes towards these 
collective modes of knowledge produc-
tion and application. Such networks 
seem to be an important component of 
the emerging knowledge-based econo-
mies in which knowledge is crucial for 
economic growth and competitiveness. 
For some authors, the omni-present 
networks even "constitute the new 
social morphology of our societies” 
(Castells 2000: 500) which are accord-
ingly labelled as network societies. 
However, this suggests that network 
formation follows some global and 
universal trend affecting, unifying, and 
arranging all parts of society in "vari-
able geometries” (Castells 2000) where 
heterogeneity and diversity is sacri-
ficed for a single over-powering pat-
tern of development. As we have 
mentioned elsewhere (Pyka/Ahrweiler 
2004), this view does not take into 
account the complex reality of eco-
nomic phenomena deeply intertwined 
with cognitive, institutional, organisa-
tional and political aspects, i.e. a world 
of institutional variety, historicity and 
path-dependence. 
In this article, we argue that the rela-
tion between knowledge, networks 
and heterogeneous institutional 
frameworks is much more complicated 
than acknowledged by the protago-
nists of "globalisation” or the so-called 
network society. Network formation is, 
on the one hand, closely linked to the 
knowledge-intensity of a few indus-
tries and, on the other, not substitut-
ing but complementing the influence 
of institutional frameworks in order to 
co-ordinate economic action. The next 
paragraphs will work out these propo-
sitions in more detail. 
 
2 Institutions matter 
"At the start of the twenty-first century 
the role of institutions and the condi-
tions for institutional change are at the 
core of the economic debate in 
Europe” (Amable 2003: 1). Neo-
institutional approaches (e.g. North 
1981; Olson 1984) claim that institu-
tions shape the structure and dynam-
ics of societies: they emphasise that 
each national society has developed a 
context and path dependent institu-
tional infrastructure (politics, law, 
economy, culture). Economic actions 
are strongly influenced by these spe-
cific infrastructures, which accordingly 
lead to different national industrial 
structures and performances. 
2.1 Varieties of Capitalism 
Although, as the sociological "varieties 
of capitalism” (VoC) thesis states, 
national industries do look different, 
each formation can offer a particular 
comparative institutional advantage 
enabling economic success within the 
different national frameworks 
(Hall/Soskice 2001). VoC studies (e.g. 
Petit/Amable 2001; Amable 2003) 
maintain that UK and Germany have 
completely different institutional 
infrastructures: while the UK is la-
belled as a "liberal market economy”, 
Germany is deemed to be a "co-
ordinated market economy”. The 
differences are traced back to national 
regulations of labour and corporate 
law, to institutional differences in 
competence development and tech-
nology transfer, and to differences in 
financial systems. Considering these 
wide-ranging differences in the institu-
tional frameworks in UK and Germany, 
summarised in Table 1, it seems rea-
sonable to expect substantial differ-
ences in the organisation of their 
national industries. Generally, Ger-
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many is considered to be burdened 
with an "old” institutional infrastruc-
ture compared to the UK. German 
industrial society contains nationally 
unified institutions such as large 
industrial corporations, bureaucratic 
organisations, professional manage-
ment, dual professional education 
systems, social security systems, 
labour unions and formal regulation, 
hierarchical co-ordination and a 
taylorised structure of work. As Hei-
denreich states: "There are no signs 
that Germany and other Continental 
European economies will follow the 
British lead and will get rid of their 
institutional structures developed over 
decades. These particular institutional 
settings cannot be dismissed as the old 
garbage of industrial society” (Heiden-
reich/Toepsch 1998: 14; own transla-
tion). 
Compared to the UK, some require-
ments of modern knowledge societies 
(see e.g. OECD 1996) are less likely to 
be fulfilled by the institutional infra-
structure in Germany. Focussing on 
knowledge creation, knowledge trans-
fer and the commercialisation of 
knowledge, knowledge-based econo-
mies require permanent access across 
borders between nations and firms as 
a pre-condition for economic action. 
This is needed to achieve, for example, 
quick commercialisation of scientific 
results from basic research, easy 
access to finance for risk-intensive 
projects, the motivation of scientific 
entrepreneurs, and the availability of 
participative management skills. To 
satisfy project requirements, highly-
qualified and flexible staff have to be 
able to migrate without the hindrances 
resulting from firm and education 
barriers (for German difficulties in this 
area see Soskice 1997, EPOHITE 2000). 
Table 1 summarises the issues. 
The VoC literature would seem to 
predict that innovative industries, 
characterised by a high research 
intensity, extensive capital needs, and 
high risk and uncertainty, would face 
difficult development conditions in 
Germany and would be far less devel-
oped than the UK's – and that this will 
stay as it is because institutions 
change slowly, if at all. Compared to 
the UK, the comparative advantage of 
Germany would be best maintained by 
concentrating its strength in the con-
ventional industrial sectors. 
Table 1- National institutional frameworks in Germany and the UK 
 Germany UK 
Labour Law 
regulative (coordinated sys-
tem of wage bargaining; 
constraints on employee 
dismissals) 
liberal (decentralised wage 
bargaining; fewer barriers to 
employee turnover) 
Company law 
stakeholder system (two tier 
board system plus codetermi-
nation rights for employees) 
shareholder system (minimal 
legal constraints on company 
organisation) 
Skill formation 
and technol-
ogy transfer 
organised apprenticeship 
system with substantial in-
volvement from industry. 
Close links between industry 
and technical universities in 
designing curriculum and 
research 
no formal apprenticeship 
system for vocational skills. 
Links between universities 
and firms almost exclusively 
limited to R&D activities and 
R&D personnel 
Financial 
system 
primarily bank-based with 
close links to stakeholder 
system of corporate govern-
ance; no hostile market for 
corporate control 
primarily capital market 
system, closely linked to 
market for corporate control 
and financial ownership and 
control of firms 
Source: Casper/Kettler 2001: 14 
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2.2 National Innovation Systems 
The notion of "national innovation 
systems” (NIS) was introduced to 
innovation research in the 1980s to 
emphasise the important role played 
by the specific national institutional 
settings and non-economic actors for 
the innovative performance of an 
economic system. According to Beije 
(1998), an innovation system "can be 
defined as a group of private firms, 
public research institutes, and several 
of the facilitators of innovation, who in 
interaction promote the creation of 
one or a number of technological 
innovations [within a framework of] 
institutions which promote or facilitate 
the diffusion or application of these 
technological innovations" (Beije 1998: 
256). 
The NIS approach (Lundvall 1992; 
Nelson 1993) focuses on actors and 
their interactions embedded in a 
national institutional infrastructure. 
Innovation and innovation-based 
economic performance is organised 
differently across national borders. 
Like the VoC literature, the NIS ap-
proach concentrates on "the systemic 
aspects of innovation [and of] diffusion 
and the relationship to social, institu-
tional and political factors” (Fagerberg 
2003: 141). Lundvall, additionally, 
contributes an emphasis on compe-
tence building and the learning capa-
bilities of individuals, organisations, 
regions and nations (Lund-
vall/Tomlinson 2002: 218, see the 
Aalborg-Freeman approach of NIS 
(Lundvall 1992)). Differentiating, 
elaborating and complementing the 
NIS concept, recent research targets 
sectoral systems of innovation 
(Malerba 2002), technological systems, 
regional innovation systems and local 
technology clusters (Feldman et al. 
2005). 
The NIS approach suggests a diagnosis 
similar to that of the VoC studies3. 
                                                       
3 For a detailed comparison of recent NIS 
and VoC approaches see Werle 2005. 
Balzat summarises the results of the 
2003 innovation report of the German 
Ministry of Economics: "On the nega-
tive side, Germany has problems to 
catch up with the USA and with the 
Nordic European countries in the 
development and dissemination of 
technologies such as ICT and biotech-
nology. A rapid reversal of the German 
"backwardness” in this high technol-
ogy field seems rather unlikely for 
three main reasons. First, Germany 
has lost ground in the level of ICT 
expenditure within the last decade. 
Second, the German labor market falls 
short of highly qualified workers and 
technical engineers. Third, the industry 
in the Eastern part of Germany is still 
far behind the West German in produc-
tivity levels and in the innovativeness 
of business firms” (Balzat 2004: 115). 
In order to compare different national 
institutional frameworks of innovation, 
Balzat constructed a NIS model con-
taining 54 indicators that operational-
ise 19 sub-blocks of six main NIS 
components (knowledge base, financ-
ing conditions, internationalisation, 
innovation and learning incentives, 
innovative efforts, framework condi-
tions)4. Figure 1 shows a simplified 
version of his NIS performance model. 
Using this set of indicators with the 
operationalisation mentioned in Balzat 
(2004), the differences between the 
national innovation systems of UK and 
Germany can be visualised as in Figure 
2. The different designs of the national 
innovation systems in UK and Ger-
many can easily be seen. Whereas the 
German system performs better in the 
dimensions of innovative efforts, 
knowledge base and internationalisa-
tion, the UK system shows advantages 
with respect to financing conditions,.
                                                       
4 For a discussion of parameter construc-
tion, indicator building and interpretation 
of results, see Balzat 2004: 156-218. 
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learning incentives and framework 
conditions, all features important for 
the evolution of entrepreneurial indus-
tries. Summarising, both the VOC and 
the NIS approaches leave us with the 
same set of research hypotheses about 
Germany's and the UK's knowledge-
based innovation. For the UK, as the 
example par excellence of a liberal 
market economy (Amable 2003), we 
expect entrepreneurial knowledge-
intensive industries supported by 
progressive venture capital focussing 
on blockbusters following radical 
product innovation strategies. For 
Germany, as the example par excel-
lence for a co-ordinated market econ-
omy (Amable 2003), we expect, mutatis 
mutandis, industries with a small rate 
of entry, conservative venture capital if 
any, and focussing on incremental 
innovation, i.e. process innovation. 
Figure 1: Indicators for comparing different institutional frameworks 
(Source: Balzat 2004: 158) 
Employment-related factors 
Private R&D spending 
Public R&D spending 
Gross domestic R&D spending 
Macroeconomic framework 
R&D incentives 
Diffusion of ICT 
Tax burden 
Present inventiveness 
(scientific success) 
Future inventiveness 
(real measures) 
Future inventiveness 
(monetary measures) 
VC availability 
Financial market costs 
Financial market institutions 
Capital market openness 
Science and education 
FDI inflows 
High-tech trade 
Innovation and learning
incentives 
Innovative efforts 
 
Framework conditions 
 
Knowledge base 
 
Financing conditions 
 
Internationalization 
 
NIS 
 
Present inventiveness 
(personal) 
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3 Institutions matter but… 
There seems to be general agreement 
about the varying institutional frame-
works of UK and Germany. For the 
manufacturing industries, in the last 
twenty years this has lead to divergent 
developments in Germany and Britain 
(e.g. machine tools and car manufac-
turing, for an overview comparing 
industrial structures in both countries 
cf. Matraves 1997). As the varieties of 
capitalism hypothesis states, this is 
also – and even especially – expected 
for the knowledge-intensive industries. 
In the following sections we shall 
consider the so-called "red” biotech-
nology sector, which covers pharma-
ceutical applications of molecular 
biology, also often referred to as 
"biopharmaceuticals”. Contrary to the 
expectations we derived from the VoC 
and NIS approaches, we shall observe 
striking structural and procedural 
similarities. The biopharmaceutical 
industries of the two countries have 
become more and more similar both in 
their focus on product and process 
technologies, and in the make-up of 
their industrial organisations (clusters, 
start-ups, spin-offs etc.). 
 
3.1 Empirical evidence: the biophar-
maceutical sector 
In this section we will present some 
statistics describing the bio-
pharmaceutical industries in the 
United Kingdom (UK) and in Germany 
(D).5 
Figure 3 demonstrates market sizes 
and their growth, measured by the 
percentage of GDP of pharmaceutical 
sales. The markets are of similar size 
in both economies and the trends 
show the same direction. 
Figure 4 compares the markets for 
pharmaceuticals in UK and D by de-
picting the market shares of novelties 
introduced by national companies 
within the last 5 years. Again the 
development and the overall sizes are 
rather similar for Germany and the 
United Kingdom. However, the German 
figure is slightly above the British 
figure over the whole time period. 
                                                       
5 Except that, in some cases, the data we 
would like to have presented is not avail-
able and so we have used data about the 
pharmaceutical sector as a whole. A con-
siderable part of the new technologies in 
the pharmaceutical sector are based on 
methods from biotechnology. 
Figure 2 - Comparing NIS components of UK and Germany 
Innovative efforts
Knowledge base
Financing conditions
Innovation and learning incentives
Framework conditions
Internationalization
Germany
United Kingdom (Source: Balzat 2004) 
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Figure 5 - International comparison of the number of core biotech firms 
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Figure 4 - Share of innovations in the pharmaceutical market in UK 
and D 
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Figure 3 - Market Size in UK and D 
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Figure 5 describes the size of the 
biotech firm population. For 2003, 
Ernst & Young (2004) records a rather 
similar number of firms in the two 
nations. If we look at the development 
of the firm population over time (Fig-
ure 6) we see that the number of 
German biotech firms has increased 
continuously and since 1999 is even 
slightly greater than the number in the 
UK in the same years. 
If we examine the number of venture 
capital (VC) cooperations in both 
countries shown in figure 7, a corre-
sponding similarity can be observed. 
The number of deals in Germany is 
slightly above those in the United 
Kingdom, whereas the amount of 
money involved in transactions is 
higher in the United Kingdom than 
Germany. 
These findings seem contrary to what 
would be expected from the VoC 
literature concerning a comparison 
between the German and the UK 
biotech industries. A considerable 
entry of firms was only expected for 
the UK; for Germany, a similar devel-
opment was not expected at all. Of 
course, a major reason for the prolif-
eration of biotech firms in Germany 
must be the huge efforts to support 
entrepreneurial behaviour coming 
from technology policy. 
 
Figure 7- VC cooperations in UK and D 
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Source: Ernst & Young, 2004  
Figure 6 - Development of private biotech firms in UK and D 
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3.2 Empirical evidence: firm strategies 
The VoC studies also suggested that 
German firms would pursue innova-
tion strategies that excluded product 
innovation, e.g. the development of 
therapeutics, expecting this country to 
stick with process innovation. Instead, 
data from 2004 show that more than 
half (56%) of the German biotech 
companies consider the development 
of therapeutics as their main area of 
action. A more detailed comparison 
from 2002 also points in this direction: 
In 2004, 32 firms in each country were 
developing therapeutics that had 
already reached the clinical phase. 
Managers from UK and Germany 
reported similar reasons for their 
strategic decisions (Ernst & Young 
2004). Chances, possibilities and risks 
are estimated in similar ways by man-
agers in the two countries. A compari-
son of the number of new drugs intro-
duced to the market in both countries 
(figure 8) shows that also the final 
outcome in UK and Germany is rela-
tively similar. 
Figure 9 shows German and British 
R&D efforts in an international com-
parison. The relative position of Ger-
many slightly worsens in the time 
period shown, but both nations have 
very similar shares of the global total. 
In Figure 10 we see the percentage of 
all pharmaceutical patents awarded to 
a country divided by the percentage of 
R&D efforts of its pharmaceutical 
industry, a measure of R&D efficiency. 
The efficiency for UK is higher over the 
four periods investigated. However, 
again the trend is in the same direction 
for both countries. 
Figure 11 shows the time elapsing 
between the first application in any 
market and the launch in the particular 
national market in Germany and UK. 
The three main reasons for delay are 
company strategy (when to apply, 
when to launch), the length of the 
regulatory process, and the length of 
the pricing and reimbursement proc-
ess. The time between approval and 
launch in the national market is 
somewhat shorter in Germany com-
pared to the United Kingdom. How-
ever, in Germany it takes considerably 
longer if the time span between the 
first application and the application to 
the national market is considered. The 
regulatory conditions in Germany are 
accordingly less favourable in this 
single respect. 
This section has clearly indicated the 
overall structural similarity of UK's and 
Germany's biopharmaceutical indus-
tries. The similarity is also visible from 
other countries: the foreign direct 
investment (FDI) inflows show that 
Germany, a 'co-ordinated' market 
economy according to the VoC thesis, 
is deemed as attractive as the UK, a 
'liberal' market economy. Table 3 
signifies the general FDI inflows for 
certain years without distinguishing 
sectors (here, Germany even overtakes 
the UK). While there is no data specifi-
cally for the biopharmaceutical sector, 
FDI Media Information (2005) shows 
that there were 23 FDI projects in the 
UK and 18 in Germany for the pharma-
ceutical sector as a whole. 
 
Table 3: FDI inflows (as a % of GDP) 
 1995 1999 2002 
UK 1,8% 5,8% 1,6% 
D 0,5% 2,6% 1,9% 
Source: PICTF 2004 
Table 2: Products in pipeline in 2002: 
comparison of Germany and UK 
  Germany UK 
Products in 
pipeline 
200 194 
* pre-clinical 117 65 
* clinical phase I 34 50 
* clinical phase II 22 56 
* clinical phase III 3 23 
 
Source: Ernst & Young 2004 
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Figure 8 - Number of drugs introduced by UK and German firms 
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Figure 9 - Relative weight of research in the pharmaceutical industries 
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Figure 10 - R&D efficiency 
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Having now presented empirical sup-
port to show that the postulated 
differences between the German and 
British economies fail to be revealed 
when the recent development of bio-
pharmaceuticals is examined, the 
observed convergence needs explana-
tion. 
 
3.3 Explaining the data: organisa-
tional alignment via innovation 
networks 
Why do we observe these strong 
similarities in comparing the UK's and 
Germany's biopharmaceutical indus-
tries? The data summarised in the 
previous sections clearly offer no 
support for the research hypotheses 
arising from the VoC and NIS literature 
that predicted large differences in the 
two national settings. One possibility 
is that the national innovation sys-
tems, i.e. the institutional frameworks, 
of both countries, have themselves 
converged. However, this potential 
explanation is ruled out by recent 
studies focussing on their persistent 
differences (cf. Amable/Barré/Boyer 
1997; Balzat 2004). Another potential 
explanation could be that the bio-
pharmaceutical sector has some 
special characteristics which might 
overwhelm the effects of national 
institutional differences. 
Our hypothesis is that all knowledge-
intensive industries have characteris-
tics which differ greatly from other 
industrial sectors: these characteristics 
directly affect innovation performance 
and provoke network formation and 
internationalisation. In the long run, 
the network effects of collaborative 
innovation mitigate or even overcome 
the effects of differences in institu-
tional frameworks. 
What are the special characteristics of 
the biopharmaceutical sector that 
trigger interactional collaborative 
innovation? Taking drug development 
as the most prominent feature of 
radical innovation in the biopharma-
ceutical industries, the first character-
istic is the demand for up-to-date 
expertise which requires a permanent 
connection with the frontiers of re-
search. For example, Herrera (2001) 
states: "research is the engine of 
Europe's Biotech Industry". Biotech 
firms are permanently "operating at 
the cutting edge of a set of technolo-
gies" (ibid) closely connected to uni-
versities and public research organisa-
tions. Furthermore, the development 
of a single drug needs a combination 
of different knowledge stocks and 
specialised expertise in a number of 
fields; it requires, for example, exten-
sive clinical testing. Small firms such 
as university spin-offs have to build up 
a close connection to hospitals and big 
pharmaceutical firms in order to get 
access to relevant knowledge in these 
areas. 
Because biopharmaceutical innova-
tions rely on 'combinatorial technolo-
Figure 11: Time spans for market introduction 
of novelties 
Germany  
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gies', large firms also have a need for 
networking: "Vertical integration is no 
longer the only way for pharmaceutical 
companies to have access to comple-
mentary and specific assets, especially 
at the first stage of cooperation. They 
take advantage of the complementary 
and combinatorial nature of biotech-
nologies to conceive new organisa-
tional forms within a cooperative 
relationship with both start-ups and 
public or quasi-public research organi-
sations. Most pharmaceutical compa-
nies are engaged in more or less 
complex operations such as mergers 
and acquisitions, joint ventures, cross-
licensing and, more generally multi-
firm alliances. They often involve 
several bilateral strategic alliances 
with different actors. In this context, 
the strategy is to focus on many part-
nerships with widely diverse compe-
tencies and goals. At the industry level, 
this leads to a very complex mapping 
of ties between actors" (Staropoli 1998: 
13-23). 
How can these high demands for 
expertise, knowledge and R&D in 
various disciplinary fields be satisfied 
when they require the collaboration of 
actors from all over the world located 
in different types of organisations? By 
using the national public and private 
R&D efforts as input indicators and the 
number of national patents and other 
similar measures as output indicators, 
the VoC and NIS literatures conclude 
that national knowledge bases are 
restricted. External and in particular 
foreign knowledge sources are not 
adequately considered. Facing the 
global knowledge requirements men-
tioned above, these restrictions must 
be overcome on the firm level by 
actors who combine their compe-
tences and expertises – competences 
that cannot necessarily be found only 
at the national level. Innovation per-
formance in knowledge-intensive 
industries, either incremental or radi-
cal, can only be achieved via interna-
tional and inter-organisational part-
nerships. 
Accordingly, we observe high and 
increasing collaborative activity in 
knowledge-intensive industries. Illus-
trating the general trend, figure 12 
shows the new international strategic 
technology alliances for IT and bio-
technology. The amount of collabora-
tive activity at least matches and 
sometimes overtakes the cumulative 
number of collaborations for all other 
Figure 12: Increasing network activity in knowledge-intensive industries 
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0
20
40
60
80
100
120
19
80
19
82
19
84
19
86
19
88
19
90
19
92
19
94
19
96
19
98
20
00
  Biotechnology Information Technologies
Source: Science and Engineering Indicators, 2002
 
Ahrweiler/Gilbert/Pyka: Institutions matter but ... 15 
 
 
technologies (National Science Board 
2002 Fig. 2-36). 
In knowledge-intensive industries 
network formation does not seem to 
be a passing phenomenon, which 
disappears with the maturation of the 
industry. Instead, networks persist as 
the main structuring principle of the 
biotech industry despite firms chang-
ing their components, attachment 
strategies and structural properties. 
For example, in the UK and German 
biopharmaceutical industries, collabo-
rative activity can be observed as a 
permanent feature. Collaboration is so 
important that a number of "match-
making” firms (e.g. Pharmalicensing 
Intl. Inc., BioScan) have been estab-
lished whose role is to inform compa-
nies about possible international 
partners. 
For example, 86 percent of German 
dedicated biotechnology firms have 
R&D partnerships either with other 
firms or with research organisations 
(EBIS 2000). Not surprisingly, for both 
Germany and the UK, we observe a 
strong increase of collaborative activity 
in the early phase of the development 
of their biotech industries because of 
missing absorptive capacities and the 
inflexibility of established big firms 
(large diversified firms, LDFs), which 
have to rely on specialised small high 
tech enterprises (dedicated biotech 
firms, DBFs) to act as translators in 
order to bridge knowledge gaps 
(Pyka/Saviotti 2005). For their part, 
DBFs need the LDFs as commercialis-
ers of their technological knowledge. 
As a result, we observe a change of the 
sectoral knowledge base: LDFs collect 
competences via fusions and acquisi-
tions; and DBFs and LDFs form net-
works in order to benefit from one 
another's competences. The observed 
early co-operations between LDFs and 
DBFs are not restricted to a national 
level, as can be seen in table 4. 
Later in the development of the sector, 
the composition, attachment strategies 
and structural properties of the net-
works change to a stronger focus on 
DBF-DBF partnerships and to the 
growth of financing as a tie between 
firms, in addition to R&D links (for a 
description of a similar evolution of 
network dynamics in the US biotech 
industries, see Powell et al. 2005). The 
Table 4: Examples of international LDF-DBF networks 
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Affymax 2     1 1  1 2      
Affymetrix 1       2        
ArQule 2       1        
British Biotech. 1     2    1 1 2    
Celltech   1      2     2 
Chiron       1 1  1   1   
CoCensys 1         1   1   
Human Genome Scie.        1    3    
Incyte Pharma  1   1  1   1 1 1    
Millenium Bio Therap. 1    2   1        
Neurogen 1          3     
Onyx  1   1        2   
Repligen     1 1   2 1 2     
Scios    1 1  1 1   1     
Sequana Therap.   1   1  1     1   
SIBIA     1 1    1      
Xenova                         2   
Source: Pyka/Saviotti 2000: 28 
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trend towards international network 
formation also increases. Figure 13 
shows the co-patenting activity of 
German and UK biotech firms with 
foreign partners.  
UK firms have a higher proportion of 
co-patents but have less patents in 
total, which means that the two curves 
converge, providing yet more evidence 
of the similarities of the industries in 
the two countries, noted above. 
Another factor leading to network 
formation and internationalisation is 
the biopharmaceutical industry's need 
for capital. To develop a new drug, 
capital of about 600 Mill. EUR must 
typically be available and the develop-
ment will need a period of about 10-12 
years until the point when commer-
cialisation is a possibility. The im-
mense resources required for R&D, 
clinical testing and marketing exceed 
the capabilities of single firms. The 
risks and uncertainty inherent in new 
drug development are indicated by the 
high exit rate of projects and firms. 
When Germany is stated in the VoC 
and NIS literature to be at a disadvan-
tage in the area of radical innovations 
such as drug development or in suc-
cessfully establishing knowledge-
based industries as a whole, it is the 
capital requirements and risks that are 
mainly considered. Summarising, it is 
argued (Casper/Kettler, 2001: 16f.) that 
the national institutional framework in 
Germany makes money scarce for risk-
intensive and expensive projects (see 
above). However, this is true – at least 
in these dimensions – for any national 
economy, including the UK. To over-
come the problem, network formation 
is the strategy of choice in both Ger-
many and the UK. The missing re-
sources are gained within globally-
oriented innovation networks (interna-
tional VC-DBF partnerships; interna-
tional DBF-LDF partnerships, cross-
border mergers and acquisitions). In 
addition we have shown in section 3.2 
that foreign direct investment is im-
portant for the biotechnology-based 
industries as an external source for 
financing innovation. 
 
4 Conclusions 
National frameworks alone cannot 
provide the necessary knowledge 
stocks and financial resources to 
produce innovation in knowledge-
Figure 13: Biotechnology patents (UK and D) with foreign partners 
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intensive industries. Complementing 
the collaborative activity on the na-
tional and regional level which is 
already significant, we observe in-
creasing international network forma-
tion as the main organisational feature 
of research and production. These 
collaborations are intended to alleviate 
the disadvantages stemming from the 
restrictions of national institutional 
infrastructures. 
While heterogeneity persists at the 
level of institutional frameworks and 
path-dependent innovation environ-
ments, the differences are of decreas-
ing relevance in knowledge-intensive 
industries, where networks dominate 
industrial organisation and lead to 
convergence and alignment. In knowl-
edge-intensive sectors such as the 
biopharmaceutical industry, the neces-
sities of knowledge exchange, transfer, 
co-operation and diffusion between 
firms leads to a strong structural and 
dynamic alignment of national indus-
tries. Inter-organisational networks 
seem to offer a kind of "second order 
co-ordination” alongside institutional 
frameworks shaping economic action. 
Commonalities and differences of 
different "capitalisms” (as proposed by 
the VoC approach) or national institu-
tional frameworks (the NIS approach) 
must be re-considered for modern 
knowledge societies. 
Research is necessary to show how 
networks perform this alignment 
process and which network features 
qualify for what organisational re-
flexes. Social network analysis (e.g. 
Granovetter/Swedberg 2001; Kadushin 
2004) suggests that dense networks 
(e.g. those now being established in 
the knowledge-based industries) tend 
to show the alignment of members and 
processes as a typical effect due to 
knowledge distribution in networks. 
The network members become more 
similar not only in their knowledge but 
also in their intentions and strategic 
behaviour. Agent-based modelling of 
network formation in knowledge-
based industries (Gilbert et al 2001, 
Ahrweiler/Pyka/Gilbert 2004) sheds 
some light on the procedural aspects 
of these issues. Nevertheless, further 
theoretical, empirical and modelling 
efforts are required to work on the 
complex features of innovation dy-
namics and industrial organisation in 
knowledge-based economies. 
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